According to a new report Asia Pacific Pneumonia Vaccines Market, published by KBV research, the Asia Pacific Pneumonia Vaccines Market would witness market growth of 6.2% CAGR during the forecast period (2019-2025).
The Prevnar 13 market dominated the Asia Pacific Pneumonia Vaccines Market by Product Type in 2018, growing at a CAGR of 5.2 % during the forecast period. The Synflorix market is expected to witness a CAGR of 8.6% during (2019 - 2025). Additionally, The Pneumovax23 market is expected to witness highest CAGR of 10% during (2019 - 2025).
The China market dominated the Asia Pacific Distribution Partner Companies Market by Region in 2018, growing at a CAGR of 3.3 % during the forecast period. The Japan market is expected to witness a CAGR of 4.8% during (2019 - 2025). Additionally, The India market is expected to witness a CAGR of 6% during (2019 - 2025).
The Pneumococcal Conjugate Vaccine (PCV) market dominated the India Pneumonia Vaccines Market by Type in 2018, thereby, achieving a market value of $262.8 million by 2025, growing at a CAGR of 5.9 % during the forecast period. The Pneumococcal Polysaccharide Vaccine (PPSV/PPV) market is expected to witness a CAGR of 9.1% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/asia-pacific-pneumonia-vaccines-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.
By Vaccine Type
By Product Type
By Sector
By Distribution Channel
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
